
REACH
30 May 2025
CAP-XX Limited
("CAP-XX" or the "Company")
Updated website
CAP-XX Limited (LSE: CPX), a global leader in supercapacitor technology, is pleased to announce the launch of an updated website and a new corporate logo. The Company's website address has not changed and the updated website can be found at www.cap-xx.com/.
The website address of CAP-XX's AIM Rule 26 disclosures has not changed and remains as www.cap-xx.com/investors/aim-rule-26.
For further information contact:
CAP-XX Limited
Dr. Graham Cooley (Chairman) +61 (2) 9157 0000
Lars Stegmann (Chief Executive Officer)
Allenby Capital (Nominated Adviser and Broker)
David Hart / Piers Shimwell (Corporate Finance) +44 (0) 20 3328 5656
Jos Pinnington / Tony Quirke (Sales and Corporate Broking)
Notes to Editors:
About CAP-XX
CAP-XX (LSE: CPX) is a leader in the design and manufacture of thin, flat supercapacitors and energy management systems used in portable and small-scale electronic devices, and to an increasing extent, in larger applications such as automotive and renewable energy. The unique feature of CAP-XX supercapacitors is their very high-power density and high energy storage capacity in a space-efficient prismatic package. These attributes are essential in power-hungry consumer and industrial electronics and deliver similar benefits in automotive and other transportation applications.
For more information visit www.cap-xx.com
About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.